Work Here?
Genesis Therapeutics
Work Here?
AI-driven drug discovery for pharmaceuticals
Genesis Therapeutics
Work Here?
AI-driven drug discovery for pharmaceuticals
About Genesis Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$280.1M
Headquarters
Burlingame, California
Founded
2019
Overview
Genesis Therapeutics develops new medicines using artificial intelligence in the drug discovery process. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. It primarily serves other biotech and pharmaceutical companies, generating revenue through strategic partnerships and funding rounds. The goal is to accelerate drug discovery and provide valuable services to its partners.
Simplify's Take
What believers are saying
- Partnership with NVIDIA enhances AI capabilities for drug discovery.
- Strategic collaborations expand therapeutic pipeline and address unmet medical needs.
- Recognition as a 'Fierce 15' company boosts industry credibility.
What critics are saying
- High competition from AI-driven drug discovery companies like Insilico Medicine.
- Over-reliance on partnerships could lead to financial instability.
- Rapid AI advancements may render current models obsolete without continuous innovation.
What makes Genesis Therapeutics unique
- Genesis uses 3D spatial graph modeling for novel drug candidate generation.
- The GEMS platform leverages physics-inspired AI for drug discovery.
- Genesis collaborates with major pharma companies like Eli Lilly and Gilead.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$280.1M
Above
Industry Average
Funded Over
3 Rounds
Andreessen HorowitzIndustry standards
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 1%Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.
Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
Genesis Therapeutics is Hiring for 20 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Genesis Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$280.1M
Headquarters
Burlingame, California
Founded
2019
Genesis Therapeutics is Hiring for 20 Jobs on Simplify!
Find jobs on Simplify and start your career today